M Rutkowski1, A Wojciechowska1, W Śmigielski2, W Drygas3,4, A Piwońska3, A Pająk5, A Tykarski6, K Kozakiewicz7, M K Waśniewska4, T Zdrojewski1. 1. Department of Hypertension and Diabetology, Medical University of Gdansk, Gdansk, Poland. 2. Unit of Demography and Social Gerontology, University of Lodz, Lodz, Poland. 3. Department of Epidemiology, Cardiovascular Disease Prevention, and Health Promotion, Institute of Cardiology, Warsaw, Poland. 4. Department of Social and Preventive Medicine, Medical University of Lodz, Lodz, Poland. 5. Epidemiology and Population Studies Department, Institute of Public Health, Jagiellonian University Medical College, Krakow, Poland. 6. Department of Hypertension, Angiology, and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland. 7. Third Department of Cardiology, Medical University of Silesia, Katowice, Poland.
Abstract
AIMS: To evaluate the prevalence of diabetes and impaired fasting glucose in Poland in 2013-2014 and to determine the temporal trends between 2003-2005 and 2013-2014. METHODS: A questionnaire survey was conducted in a representative sample of Polish adults, complemented by anthropometric and fasting plasma glucose measurements. The research was part of the national cross-sectional WOBASZ study. Diabetes was assessed as self-reported or screened (fasting plasma glucose level ≥ 7 mmol/l, based on one blood sample). RESULTS: In the years 2013-2014 among 5694 participants aged 20-74 years, 6.0% (95% CI 5.4-6.6) reported a previous diagnosis of diabetes (5.8% in women and 6.2% in men). In addition, 2.4% of the participants (95% CI 2.0-2.8) without a previous diagnosis of diabetes (1.8% of women and 3.1% of men) had a fasting blood glucose level ≥7.0 mmol/l in a single measurement. In a single measurement, 18.4% of the participants (95% CI 17.4-19.4; 13.2% of women and 23.8% of men) had impaired fasting glucose. The prevalence of dysglycaemia in the WOBASZ II study was significantly higher compared to the WOBASZ I study findings from 2003-2005, increased from 6.6% to 8.4% for diabetes and from 9.3% to 18.4% for impaired fasting glucose (after age and sex standardization to the 2013 Polish population). CONCLUSIONS: The prevalence of diabetes in Poland is similar to that observed in other European populations and has increased significantly over the last decade.
AIMS: To evaluate the prevalence of diabetes and impaired fasting glucose in Poland in 2013-2014 and to determine the temporal trends between 2003-2005 and 2013-2014. METHODS: A questionnaire survey was conducted in a representative sample of Polish adults, complemented by anthropometric and fasting plasma glucose measurements. The research was part of the national cross-sectional WOBASZ study. Diabetes was assessed as self-reported or screened (fasting plasma glucose level ≥ 7 mmol/l, based on one blood sample). RESULTS: In the years 2013-2014 among 5694 participants aged 20-74 years, 6.0% (95% CI 5.4-6.6) reported a previous diagnosis of diabetes (5.8% in women and 6.2% in men). In addition, 2.4% of the participants (95% CI 2.0-2.8) without a previous diagnosis of diabetes (1.8% of women and 3.1% of men) had a fasting blood glucose level ≥7.0 mmol/l in a single measurement. In a single measurement, 18.4% of the participants (95% CI 17.4-19.4; 13.2% of women and 23.8% of men) had impaired fasting glucose. The prevalence of dysglycaemia in the WOBASZ II study was significantly higher compared to the WOBASZ I study findings from 2003-2005, increased from 6.6% to 8.4% for diabetes and from 9.3% to 18.4% for impaired fasting glucose (after age and sex standardization to the 2013 Polish population). CONCLUSIONS: The prevalence of diabetes in Poland is similar to that observed in other European populations and has increased significantly over the last decade.
Authors: Natalia Drobek; Paweł Sowa; Piotr Jankowski; Maciej Haberka; Zbigniew Gąsior; Dariusz Kosior; Danuta Czarnecka; Andrzej Pająk; Karolina Szostak-Janiak; Agnieszka Krzykwa; Małgorzata Setny; Paweł Kozieł; Marlena Paniczko; Jacek Jamiołkowski; Irina Kowalska; Karol Kamiński Journal: J Clin Med Date: 2021-05-05 Impact factor: 4.241